Regulation & law · 30/11/2018
National Cancer Institute Considers Exclusive Patent License to Bull Run Capital for Cancer Research
The National Cancer Institute, part of the National Institutes of Health, is evaluating a potential exclusive patent license to Bull Run Capital, a Canadian company, to utilize its patented cancer research compositions and methods.